Reuters logo
BRIEF-Regeneron, Teva provide update on fasinumab clinical development programs
October 17, 2016 / 11:32 AM / a year ago

BRIEF-Regeneron, Teva provide update on fasinumab clinical development programs

Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc

* Regeneron and Teva provide update on fasinumab clinical development programs

* Regeneron Pharmaceuticals Inc - FDA has placed phase 2B study in chronic low back pain on clinical hold

* Regeneron - FDA requested amendment of study protocol after observing case of adjudicated arthropathy in a patient receiving high dose fasinumab

* Regeneron- A separate agreement with co , Mitsubishi Tanabe Pharma has exclusive development, commercial rights to fasinumab in Japan, Korea ,9 countries Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below